Jackson State University

U54MD015929

The mission of RCMI Center for Health Disparities Research (RCHDR) at Jackson State University (JSU) isto conduct innovative biomedical, socio-behavioral, clinical, and/or translational research aimed at improving minority health and reducing or eliminating health disparities in Mississippi. RCHDR accomplishes its mission through strategic investments in critical research infrastructure, community engagement, and training/building a critical mass of biomedical scientists to address important health disparities issues of concern to vulnerable and underserved communities. The Center has established an excellent research ecosystem that fosters scientific discoveries and team science to maximize research productivity.

Principal Investigator

Tchounwou, Paul

Learn More

Contact PI

Jackson State University Projects | Go to Research Database

6 Results | EXPORT RESULTS

Project / Principal Investigator / Organization	Admin IC	Funding IC	FY Total Costs By IC	Fiscal Year
RCMI Center for Health Disparities Research TCHOUNWOU, PAUL B \| JACKSON STATE UNIVERSITY	NIMHD	NIDA, NIMHD	2310074$2,310,074	2022
Administrative Core TCHOUNWOU, PAUL B \| JACKSON STATE UNIVERSITY	NIMHD	NIMHD	528299$528,299	2022
Research Infrastructure Core STEVENS, JACQUELINE JEANETTE \| JACKSON STATE UNIVERSITY	NIMHD	NIMHD	622146$622,146	2022
Investigator Development Core TURNER, TIMOTHY \| JACKSON STATE UNIVERSITY	NIMHD	NIMHD	390056$390,056	2022
Community Engagement Core ANTOINE-LAVIGNE, DONNA A \| JACKSON STATE UNIVERSITY	NIMHD	NIMHD	227764$227,764	2022
Strengthening the Biomedical Data Science Training Program at Jackson State University TCHOUNWOU, PAUL B \| JACKSON STATE UNIVERSITY	NIMHD	OD	377500$377,500	2022

RCMI News

September 26, 2022November 16, 2022

p53 as a unique target of action of cisplatin in acute leukaemia cells

Kumar S, Tchounwou PB. p53 as a unique target of action of cisplatin in acute leukaemia cells. J Cell Mol Med. 2022 Sep;26(17):4727-4739. doi: 10.1111/jcmm.17502…. Continue Reading

September 17, 2022November 16, 2022

CXC Chemokines in the Pathogenesis of Pulmonary Disease and Pharmacological Relevance

Komolafe K, Pacurari M. CXC Chemokines in the Pathogenesis of Pulmonary Disease and Pharmacological Relevance. Int J Inflam. 2022 Sep 17;2022:4558159. doi: 10.1155/2022/4558159. PMID: 36164329;… Continue Reading

September 9, 2022November 16, 2022

Inhibition of insulin-like growth factor 2 mRNA-binding protein 1 sensitizes colorectal cancer cells to chemotherapeutics

Betson N, Hajahmed M, Gebretsadek T, et al. Inhibition of insulin-like growth factor 2 mRNA-binding protein 1 sensitizes colorectal cancer cells tochemotherapeutics. FASEB BioAdvances. 2022;00:1-14…. Continue Reading

Unlocking the mechanism of action of arsenic trioxide in leukaemia

The discovery of the molecular mechanism of ATO action has the potential to make a significant contribution to the development of more targeted approaches to treat acute promyelocytic leukaemia and other human cancers. Our groundbreaking research has allowed us to identify several important targets that play a critical role in cancer initiation, promotion, and progression.

Learn More

Inhibition of insulin-like growth factor 2 mRNA-binding protein 1 sensitizes colorectal cancer cells to chemotherapeutics

This study portrays the insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) as an attractive target for colorectal cancer treatment. Inhibition of IGF2BP1 potentiates the anti-growth effects of drugs on colorectal cancer cells. This was associated with a significant increase in cell death and reduction in the migratory capability of those cells. Inhibition of IGF2BP1 was sufficient to decrease the resistance of some cancer cells to drugs. This was paralleled with a significant reduction in the multidrug resistance membrane transporter genes ABCB1 and ABCG2.

Learn More

Learn more about the RCMI Center for Health Disparities Research at Jackson State University

Learn More